Editas Medicine, Inc. Quarterly Debt-to-equity in % from Q3 2016 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Editas Medicine, Inc. quarterly Debt-to-equity history and growth rate from Q3 2016 to Q3 2024.
  • Editas Medicine, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 57.2 %, a 40.2% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 57.2 +16.4 +40.2% Sep 30, 2024
Q2 2024 48 +10.6 +28.2% Jun 30, 2024
Q1 2024 41.5 +7.33 +21.5% Mar 31, 2024
Q4 2023 40.9 +12.6 +44.5% Dec 31, 2023
Q3 2023 40.8 +16.8 +70.4% Sep 30, 2023
Q2 2023 37.4 +14.8 +65.2% Jun 30, 2023
Q1 2023 34.1 +11.8 +52.6% Mar 31, 2023
Q4 2022 28.3 +5.74 +25.5% Dec 31, 2022
Q3 2022 23.9 -2.68 -10.1% Sep 30, 2022
Q2 2022 22.7 -7.06 -23.8% Jun 30, 2022
Q1 2022 22.4 -14.8 -39.8% Mar 31, 2022
Q4 2021 22.5 -30.7 -57.7% Dec 31, 2021
Q3 2021 26.6 -36.6 -57.9% Sep 30, 2021
Q2 2021 29.7 -47 -61.3% Jun 30, 2021
Q1 2021 37.2 -52.1 -58.4% Mar 31, 2021
Q4 2020 53.2 -29.9 -36% Dec 31, 2020
Q3 2020 63.3 -15.1 -19.3% Sep 30, 2020
Q2 2020 76.7 -0.43 -0.56% Jun 30, 2020
Q1 2020 89.3 +15.4 +20.9% Mar 31, 2020
Q4 2019 83.1 +12.2 +17.2% Dec 31, 2019
Q3 2019 78.3 +7.35 +10.4% Sep 30, 2019
Q2 2019 77.1 +2.52 +3.38% Jun 30, 2019
Q1 2019 73.9 -7.63 -9.36% Mar 31, 2019
Q4 2018 70.9 -19 -21.2% Dec 31, 2018
Q3 2018 71 -18.3 -20.5% Sep 30, 2018
Q2 2018 74.6 -2.8 -3.62% Jun 30, 2018
Q1 2018 81.5 +21.7 +36.4% Mar 31, 2018
Q4 2017 89.9 +50.1 +126% Dec 31, 2017
Q3 2017 89.3 +44.2 +98.2% Sep 30, 2017
Q2 2017 77.4 Jun 30, 2017
Q1 2017 59.8 Mar 31, 2017
Q4 2016 39.8 Dec 31, 2016
Q3 2016 45 Sep 30, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.